[BRAF mutation detection in metastatic melanoma]

Pathologe. 2012 Jul;33(4):352-6. doi: 10.1007/s00292-012-1609-5.
[Article in German]
No abstract available

MeSH terms

  • Antineoplastic Agents / adverse effects
  • Antineoplastic Agents / therapeutic use
  • Clinical Trials, Phase III as Topic
  • Combined Modality Therapy
  • DNA Mutational Analysis*
  • Germany
  • Humans
  • Indoles / adverse effects
  • Indoles / therapeutic use
  • Lymph Nodes / pathology
  • Lymphatic Metastasis / pathology
  • Melanoma / drug therapy
  • Melanoma / genetics*
  • Melanoma / pathology
  • Melanoma / secondary*
  • Molecular Targeted Therapy
  • Proto-Oncogene Proteins B-raf / antagonists & inhibitors
  • Proto-Oncogene Proteins B-raf / genetics*
  • Quality Control
  • Randomized Controlled Trials as Topic
  • Real-Time Polymerase Chain Reaction
  • Skin Neoplasms / drug therapy
  • Skin Neoplasms / genetics*
  • Skin Neoplasms / pathology
  • Sulfonamides / adverse effects
  • Sulfonamides / therapeutic use
  • Vemurafenib

Substances

  • Antineoplastic Agents
  • Indoles
  • Sulfonamides
  • Vemurafenib
  • BRAF protein, human
  • Proto-Oncogene Proteins B-raf